KELI 101
Alternative Names: KELI-101Latest Information Update: 21 Feb 2025
At a glance
- Originator Keli Therapeutics
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute kidney injury
Most Recent Events
- 07 Nov 2024 Preclinical trials in Acute kidney injury (Prevention) in Lithuania (IV), prior to November 2024
- 07 Nov 2024 Keli Therapeutics plans the phase Ib/II MesAKI trial for Acute Kidney injury (Prevention) (IV), in April 2025 (NCT06678399)